Progress towards butyrateproducing pharmabiotics: Butyricicoccus pullicaecorum capsule and efficacy in TNBS models in comparison with therapeutics

Gut

Volumn 63, Issue 2, 2014, Pages 367-

  Eeckhaut, Venessa ^a   Ducatelle, Richard ^a   Sas, Benedikt ^a   Vermeire, Séverine ^b   Van Immerseel, Filip ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE SODIUM SUCCINATE; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHARMABIOTIC AGENT; UNCLASSIFIED DRUG; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; BUTYRICICOCCUS PULLICAECORUM; CLOSTRIDIUM; COLITIS; CONTROLLED STUDY; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; LETTER; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION; ANIMAL; CROHN DISEASE; ENDOSPORE-FORMING RODS AND COCCI; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MALE; MICROBIOLOGY; NOTE; PHYSIOLOGY; ULCERATIVE COLITIS;

INFLAMMATORY BOWEL DISEASE; PROBIOTICS;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GRAM-POSITIVE ENDOSPORE-FORMING RODS; HUMANS; MALE;

EID: 84891743578     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305293     Document Type: Letter

References (2)

1. Marteau P. Butyrate-producing bacteria as pharmabiotics for inflammatory bowel disease. Gut 2013;62:1673.
2. Eeckhaut V, Machiels K, Perrier C, et al. Butyricicoccus pullicaecorum in inflammatory bowel disease. Gut 2013;62:1745-52.